DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease

American Journal of Human Genetics

Volumn 62, Issue 1, 1998, Pages 36-44

  Sanghera, Dharambir K ^a   Aston, Christopher E ^a   Saha, Nilmani ^a   Kamboh, M Ilyas ^a,b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLESTERASE;

ADULT; ARTICLE; CHROMOSOME 7; CONTROLLED STUDY; CORONARY RISK; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC LINKAGE; GENETIC RISK; HUMAN; INDIAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 0031915397     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1086/301669     Document Type: Article

References (32)

1. Adkins S, Gan KN, Mody M, La Du BN (1993) Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 52: 598-608
2. Antikainen M, Murtomaki S, Syvanne M, Pahlman R, Tahvanainen E, Jauhiamen M, Haikki Frick M, et al (1996) The Gin-Arg 191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of the coronary artery disease in Finns. J Clin Invest 98:883-885
3. Augustinsson KB (1968) The evolution of esterases in vertebrates. In: van Thoai N, Roche J (eds) Homologous enzymes and biochemical evolution. Gordon & Breach, New York, pp 299-311
4. Blatter Garin M-C, James RW, Dessoix P, Blanche H, Passa P, Froguel P, Ruiz J (1997) Paraoxonase polymorphism MetLeu 54 is associated with modified serum concentrations of the enzyme: a possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 99:62-66
5. Blatter Garin M-C, James RW, Messmer S, Barja F, Pometta D (1993) Identification of high density lipoprotein subspecies defined by a lipoprotein-associated protein, k-45. Eur J Biochem 211:871-879
6. Davies HG, Rebecca JR, Keifer M, Broomfield CA, Sowalla J, Furlong CE (1996) The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 4:334-336
7. Diepgen TL, Geldmacher-von Mallinckrodt M (1986) Interethnic differences in the detoxification of organophosphates: the human serum paraoxonase polymorphism. Arch Toxicol Suppl 9:154-158
8. Furlong CE, Richter RJ, Seidel SL, Motulsky AG (1988) Role of genetic polymorphism of human paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet 43:230-238
9. Herrmann S-M, Blanc H, Poirier O, Arveiler D, Luc G, Evans A, Marques Vidal P, et al (1996) The Gin/Arg polymorphism of the human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis 126: 299-303
10. Hill WG (1974) Estimation of linkage disequilibrium in randomly mating populations. Heredity 33:229-239
11. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE (1993) The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3: 73-76
12. Kelso GJ, Stuart WD, Richter RJ, Furlong CE, Jordan-Starck TC, Harmony AK (1994) Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry 33: 832-839
13. Klimov AN, Gurevich VS, Nikiforova AA, Shatilina LV, Kuzmin AA, Plavinsky SL, Teryukova NP (1993) Antioxidative activity of high density lipoprotein in vivo. Atherosclerosis 100:13-18
14. La Du BN (1992) Human serum paraoxonase/arylesterase. In: Kalow W (ed) Pharmaco-genetics of drug metabolism. Pergamon Press, New York, pp 51-91
15. _ (1996) Structural and functional diversity of paraoxonases. Nat Med 2:1186-1187
16. La Du BN, Piko JI, Ekerson HW, Vincent-Viry M, Siest G (1988) An improved method for phenotyping individuals for the human paraoxonase/arylesterase polymorphism. Ann Biol Olin 44:369-372
17. Mackness MI, Arrol S, Abbott C, Durrington PN (1993) Protection of low density lipoprotein against oxidative modification by high density lipoprotein associated paraoxonase. Atherosclerosis 104:129-135
18. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, Durrington PN (1991) Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 86:193-199
19. Mackness MI, Peuchant E, Dumon M-F, Walker CH, Clerc M (1989) Absence of 'A'-esterase activity in serum of patients with Tangier disease. Clin Biochem 22:475-478
20. Mackness MI, Walker CH, Carson LA (1987) Low 'A'-esterase activity in serum of patients with fish-eye disease. Clin Chem 3:587-588
21. McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH (1986) Distribution of paraoxonase hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 32:671-673
22. Navab M, Berliner JA, Watson AD, Hama SY, Tritto MC, Lusis AJ, Shih DM, et al (1996) The yin and yang of the oxidation in the development of the fatty streak. Arterioscler Thromb Vasc Biol 16:831-842
23. Parzer S, Mannhalter CA (1991) Rapid method for the isolation of genomic DNA from citrate whole blood. Biochem J 273:229-231
24. Primo-Parmo SL, Hsu C, Law DJ, La Du BN (1996a) Location and arrangement of three paraoxonase genes: PON1, PON2 and PON3, on human chromosome 7. Am J Hum Genet Suppl 59:A406
25. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN (1996b) The human serum paraoxonase/arylesterase gene (PON1) is one member of multigene family. Genomics 33:498-507
26. Roy AC, Saha N, Tay JSH, Ratnam SS (1991) Serum paraoxonase polymorphism in three populations of Southeast Asia. Hum Hered 141:265-269
27. Ruiz J, Blanche H, James RW, Garin M-CB, Vaisse C, Charpentier G, Cohen N, et al (1995) Gln-Arg·192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 346:869-872
28. Sanghera DK, Saha N, Aston CE, Kamboh MI (1997) Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 17:1067-1073
29. Serrato M, Marian AJ (1995) A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 96:3005-3008
30. Sorenson RC, Primo-Parmo SL, Kuo CL, Adkins S, Lockridge O, La Du BN (1995) Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc Natl Acad Sci USA 92:7187-7191
31. Stafforini DM, Zimmerman GA, McIntyre TM (1993) The platelet activating factor acetylhydrolase from human plasma prevents oxidative modification of low density lipoprotein. Trans Assoc Am Phys 105:44-63
32. Watson AD, Berlinor JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M (1995) Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96:2882-2891